hemovigilance: are we making a difference?...johanna c. wiersum-osselton, md phd trip hemovigilance...
TRANSCRIPT
![Page 1: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/1.jpg)
Hemovigilance: are we
making a difference?
Johanna C. Wiersum-Osselton, MD PhDTRIP Hemovigilance and biovigilance and Sanquin
No financial conflicts of interest
![Page 2: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/2.jpg)
Disclaimer
• Views expressed in this presentation do notnecessarily reflect those of TRIP, Sanquin or anyother organisation with which I am affiliated
![Page 3: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/3.jpg)
1990s: Tainted blood
• Fear of infections
• Desire for transparency
![Page 4: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/4.jpg)
Global Database on Blood Safety
Infection tested Countries with
incomplete testing$
Range
HIV 7 countries 91.6% to 99.7%
HBV 9 countries 26.8% to 98.5%
HCV 11 countries 17.5% to 99%
Syphilis 9 countries* 66.0% to 98.4%
$7 countries were unable to provide a % of coverage
*3 European countries no longer routinely test for syphilis as a result of
policy change
Global status report on blood safety and availability
2016. Geneva: World Health Organization; 2017.
2013 data from156 of 195 Member States
![Page 5: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/5.jpg)
Reports to TRIP(from 2003, all severity levels)
• >95% participation
• Nearly all hospitals have transfusion safety officer
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0
500
1000
1500
2000
2500
3000
2002
2003
2004
2005
2006
2007
2008
2009
2010
2017
Report
s p
er
1000 u
nits d
istr
ibute
d
Report
s p
er
year
Totalreports
Seriousreports(grade2,3,4)
Reportsper 1000units
![Page 6: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/6.jpg)
Errors and incidents
SHOT Report 2000/1 Figure 4
Reports to SHOT in
2016 (Figure 3.3)
Possibly
preventable 121
Not preventable 282
Errors 2688
IBCT (213)
67,6%
![Page 7: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/7.jpg)
![Page 8: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/8.jpg)
French data (ANSM rapport d’activité d’hémovigilance 2016)
TR with RBC TR with plts TR with plasma Incidence, all bp
Fig. 31: ABO incompatible transfusions (imp. definite, probable), 2010-2016
Num
ber
of
transfu
sio
nre
actions
Incid
ence
per
100,0
00 t
ransfu
sio
ns
![Page 9: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/9.jpg)
IHN, ISTARE
![Page 10: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/10.jpg)
TRALI, TACO, TAD
0
20
40
60
80
100
120
20
02
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
20
16
20
17
Transfusion-associated acute lunginjury (TRALI)
Transfusion-associated circulatoryoverload (TACO)
Transfusion-associated dyspnea(TAD)
![Page 11: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/11.jpg)
Variant CJD
• Donor eligibility
• Universal leukodepletion as precautionarymeasure
• Concerns about medicinal plasma products
Seed et al, Vox Sanguinis 2018 April 113(3):220-231
![Page 12: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/12.jpg)
Global Database on Blood Safety
![Page 13: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/13.jpg)
GDBS: haemovigilance
WHO region (total no
of countries)
% hospitals
with
transfusion
committee (*)
% hospitals
participating in
adverse
reaction
reporting (*)
Haemovigilance
system (n/*)
Africa (46-47) 14% (33) 17% (26) 26% (12/42)
Americas (35) 20% (13) 91% (12) 14% (35)
Eastern Mediterranean
(20-21)
57% (13) 32% (9) 35% (7/20)
Europe (53) 92% (23) 99% (12) 77% (33/43)
South-East Asia (11) 57% (7) 59% (5) 46% (5/11)
Western Pacific (27) 25% (20) 37% (20) 32% (8/25)
Total (195) 39% (70/180)
*number of countries providing data
Global status report on blood safety and availability
2016. Geneva: World Health Organization; 2017.
![Page 14: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/14.jpg)
DonorsData from PEI, 2015
Breakdown according to IHN-ISBT-AABB definitions
“Vasovagal reactions without loss of consciousness (LOC)
were the most frequent donor reactions with 46%.”
![Page 15: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/15.jpg)
DonorsData from PEI, 2015 (2)
“Major differences existed between the donation centres with
regard to the reports. These were probably due to different
judgements of the severity of the reaction”
Guidance to support
severity assessment
under preparation
![Page 16: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/16.jpg)
Yes and no
![Page 17: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/17.jpg)
What is HV?
• Surveillance system
• A science?
• It is not an intervention
• What are the outputs to be?
What would we miss if we did not have HV?
![Page 18: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/18.jpg)
• Variable reporting
• Data quality, validation
• Severity assessment
• Learning from errors, bringing about change
• Reporting fatigue
• Need for new outcome measures
Issues (non-exhaustive)
AfSBT 19-22 June 2018
Lack of blood
Traceability
Allo-immunisation and DHTR
TACO in pediatric patients
![Page 19: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/19.jpg)
Would you volunteer?
IHN HV Quality Task Force
– Develop standards for HV systems
– Develop definitions for outcomes
• With ISBT HV working party
• Work with AfSBT on inability/failure to transfuse(list of key reasons)
• Is there a relevant indicator for management of donor iron status?
– Periodic quality audit using vignettes forclassification
– ……..
![Page 20: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/20.jpg)
IHN vision, mission and strategic goals
![Page 21: Hemovigilance: are we making a difference?...Johanna C. Wiersum-Osselton, MD PhD TRIP Hemovigilance and biovigilance andSanquin No financial conflicts of interest](https://reader035.vdocuments.us/reader035/viewer/2022071503/6122bcccff1f9d0907176969/html5/thumbnails/21.jpg)
Thank you
Colleagues at TRIP and Sanquin
All HV contacts in the Netherlands
and abroad